Julie Courraud

Dr. Julie Courraud

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Food Chemistry
Verified
Journal Article
Closed access
JCJulie Courraud
Julie Courraud
JBJacques Berger
Jacques Berger
JCJean-Paul Cristol
Jean-Paul Cristol
SASylvie Avallone
Sylvie Avallone

23 May 2018 in Acta Physiologica
Verified
Journal Article
Closed access
PDF file
MKMarianne D Kristensen
Marianne D Kristensen
SPSigne M Petersen
Signe M Petersen
KMK. E. Møller
K. E. Møller
MLMichael T Lund
Michael T Lund
MHMerethe Hansen
Merethe Hansen
CPClara Prats
Clara Prats

29 June 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
PFPaula Fernandez-Guerra
Paula Fernandez-Guerra
AGAna C. Gonzalez-Ebsen
Ana C. Gonzalez-Ebsen
SBSusanne Eriksen Boonen
Susanne Eriksen Boonen
JCJulie Courraud
Julie Courraud
NGNiels Gregersen
Niels Gregersen
LBLouise Schouborg Brinth
Louise Schouborg Brinth
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a heterogeneous, debilitating, and complex disease. Along with disabling fatigue, ME/CFS presents an array of other core symptoms, including autonomic nervous system (ANS) dysfunction, sustained inflammation, altered energy metabolism, and mitochondrial dysfunction. Here, we evaluated patients’ symptomatology and the mitochondrial metabolic parameters in peripheral blood mononuclear cells (PBMCs) and plasma from a clinically well-characterised cohort of six ME/CFS patients compared to age- and gender-matched controls. We performed a comprehensive cellular assessment using bioenergetics (extracellular flux analysis) and protein profiles (quantitative mass spectrometry-based proteomics) together with self-reported symptom measures of fatigue, ANS dysfunction, and overall physical and mental well-being. This ME/CFS cohort presented with severe fatigue, which correlated with the severity of ANS dysfunction and overall physical well-being. PBMCs from ME/CFS patients showed significantly lower mitochondrial coupling efficiency. They exhibited proteome alterations, including altered mitochondrial metabolism, centred on pyruvate dehydrogenase and coenzyme A metabolism, leading to a decreased capacity to provide adequate intracellular ATP levels. Overall, these results indicate that PBMCs from ME/CFS patients have a decreased ability to fulfill their cellular energy demands.

13 March 2023 in Journal of the American Society for Mass Spectrometry
Verified
Journal Article
Open access
FOFilip Ottosson
Filip Ottosson
FRFrancesco Russo
Francesco Russo
AAAnna Abrahamsson
Anna Abrahamsson
NMNadia MacSween
Nadia MacSween
JCJulie Courraud
Julie Courraud
MEMadeleine Ernst
Madeleine Ernst

21 June 2016 in SpringerPlus
Verified
Journal Article
Open access
PDF file
EGEstelle Guerdoux-Ninot
Estelle Guerdoux-Ninot
RKRobert D. Kilgour
Robert D. Kilgour
CJChloé Janiszewski
Chloé Janiszewski
MJMarta Jarlier
Marta Jarlier
JMJocelyne Meuric
Jocelyne Meuric
PSPierre Senesse
Pierre Senesse
The present study examined patient self-reports of descriptions, experiences and consequences of meal disturbances and food preferences within a cultural context (i.e., French meal traditions) in various treated cancer patients along their disease trajectory. Over 800 questionnaires were sent to 20 cancer treatment centres in France. During a 9-month period, 255 questionnaires were received from five centres. Inclusion criteria included those French patients over 18 years of age, could read and understand French, had an Eastern Cooperative Oncology Group score between 0 and 2, experienced treatment-induced nutrition changes and/or had decreased oral intake. Dietetic staff assessed clinical characteristics while patients completed a 17-item questionnaire. The majority of patients were diagnosed with breast, gastro-intestinal (GI) tract and head and neck cancers (62 %). Half of the patients (49 %) experienced weight loss >5 %. The main treatment-induced side effects were fatigue, nausea, dry mouth, hypersensitivity to odors and GI tract transit disorders. These discomforts affected eating and drinking in 83 % of patients, inducing appetite loss and selected food aversion. Food preference appeared heterogeneous. Food taste, odor and finally appearance stimulated appetite. Finally, dietary behaviors and satisfaction were driven by the extent to which food was enjoyed. During oncologic treatments, eating and drinking were affected in more than three-quarters of patients. As recommended by practice guidelines, nutritional assessment and follow-up are required. Personalized nutritional counseling should include the role of the family, patient’s meal traditions, and food habits.

30 January 2021 in Journal of Molecular Neuroscience
Verified
Journal Article
Open access
PDF file
JCJulie Courraud
Julie Courraud
MEMadeleine Ernst
Madeleine Ernst
SLSusan Svane Laursen
Susan Svane Laursen
DHDavid M. Hougaard
David M. Hougaard
ACArieh S. Cohen
Arieh S. Cohen
Main risk factors of autism spectrum disorder (ASD) include both genetic and non-genetic factors, especially prenatal and perinatal events. Newborn screening dried blood spot (DBS) samples have great potential for the study of early biochemical markers of disease. To study DBS strengths and limitations in the context of ASD research, we analyzed the metabolomic profiles of newborns later diagnosed with ASD. We performed LC-MS/MS-based untargeted metabolomics on DBS from 37 case-control pairs randomly selected from the iPSYCH sample. After preprocessing using MZmine 2.41, metabolites were putatively annotated using mzCloud, GNPS feature-based molecular networking, and MolNetEnhancer. A total of 4360 mass spectral features were detected, of which 150 (113 unique) could be putatively annotated at a high confidence level. Chemical structure information at a broad level could be retrieved for 1009 metabolites, covering 31 chemical classes. Although no clear distinction between cases and controls was revealed, our method covered many metabolites previously associated with ASD, suggesting that biochemical markers of ASD are present at birth and may be monitored during newborn screening. Additionally, we observed that gestational age, age at sampling, and month of birth influence the metabolomic profiles of newborn DBS, which informs us on the important confounders to address in future studies.